Zymeworks Inc. will report Q3 2025 financial results on November 6, 2025, followed by a conference call.
Quiver AI Summary
Zymeworks Inc., a Vancouver-based biotechnology company, announced its plans to release its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 4:30 pm ET to discuss the results and provide a corporate update. The company is focused on developing novel biotherapeutics to improve treatment for challenging diseases, including cancer and autoimmune conditions. One of its key products, zanidatamab, a HER2-targeted bispecific antibody, has received accelerated approval from the U.S. FDA and conditional approvals in China and Europe for specific cancer treatments. Zymeworks is actively working on expanding its pipeline, with ongoing clinical trials for ZW191 and upcoming trials for ZW251, while also engaging in strategic partnerships to enhance its therapeutic platforms.
Potential Positives
- Zymeworks has received accelerated approval for zanidatamab from the U.S. FDA, highlighting the drug's significance and potential impact on cancer treatment.
- Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for biliary tract cancer in the U.S., Europe, and China, establishing a strong competitive position.
- The company is advancing multiple clinical trials, including those for ZW191 and the expected entry of ZW251 into clinical trials in 2025, indicating a strong and active product pipeline.
- Zymeworks has established strategic partnerships with global biopharmaceutical companies, enhancing its market presence and collaborative opportunities in drug development.
Potential Negatives
- Absence of financial performance highlights or guidance could raise concerns among investors about the company's current financial health and future prospects.
- The reliance on partnerships for commercialization of its lead product, zanidatamab, may imply a lack of full control over its own product pipeline and revenues.
- Conditional approvals for zanidatamab in major markets suggest that additional efficacy or safety data may be required, potentially impacting its market position and development timeline.
FAQ
When will Zymeworks announce its Q3 2025 financial results?
Zymeworks will report its Q3 2025 financial results after market close on November 6, 2025.
What time is the conference call for the financial results?
The conference call and webcast will take place on November 6, 2025, at 4:30 pm Eastern Time (ET).
How can I access the webcast for Zymeworks' financial results?
The event will be webcast live, with details available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations.
What is zanidatamab and its significance?
Zanidatamab is the first dual HER2-targeted bispecific antibody approved for treating HER2-positive biliary tract cancer in the U.S., Europe, and China.
What other therapeutic candidates is Zymeworks developing?
Zymeworks is advancing its pipeline with candidates like ZW191 and ZW251, targeting significant unmet medical needs in oncology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZYME Insider Trading Activity
$ZYME insiders have traded $ZYME stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 3 purchases buying 110,181 shares for an estimated $1,266,404 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Hedge Fund Activity
We have seen 89 institutional investors add shares of $ZYME stock to their portfolio, and 84 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ECOR1 CAPITAL, LLC added 5,710,840 shares (+33.1%) to their portfolio in Q2 2025, for an estimated $71,671,042
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,420,432 shares (-36.6%) from their portfolio in Q2 2025, for an estimated $17,826,421
- ASSENAGON ASSET MANAGEMENT S.A. added 833,994 shares (+169.2%) to their portfolio in Q3 2025, for an estimated $14,244,617
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 766,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,625,147
- VANGUARD GROUP INC added 697,652 shares (+39.5%) to their portfolio in Q2 2025, for an estimated $8,755,532
- VESTAL POINT CAPITAL, LP added 650,000 shares (+130.0%) to their portfolio in Q2 2025, for an estimated $8,157,500
- REDMILE GROUP, LLC removed 638,318 shares (-13.3%) from their portfolio in Q2 2025, for an estimated $8,010,890
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZYME Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B. Riley Securities issued a "Buy" rating on 10/10/2025
- Citigroup issued a "Buy" rating on 08/11/2025
- TD Securities issued a "Buy" rating on 05/20/2025
To track analyst ratings and price targets for $ZYME, check out Quiver Quantitative's $ZYME forecast page.
$ZYME Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 3 analysts offer price targets for $ZYME in the last 6 months, with a median target of $26.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $26.0 on 10/14/2025
- Mayank Mamtani from B. Riley Securities set a target price of $30.0 on 10/10/2025
- Yigal Nochomovitz from Citigroup set a target price of $22.0 on 08/11/2025
Full Release
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its third quarter 2025 financial results after market close on November 6, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on November 6, 2025 at 4:30 pm Eastern Time (ET).
The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations .
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab has received accelerated approval from the U.S. FDA, conditional approval from the NMPA in China, and conditional marketing authorization from the European Commission for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. It is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China. Zanidatamab is also being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. A Phase 1 study for ZW191 is actively recruiting and ZW251 is expected to enter clinical trials in 2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit
www.zymeworks.com
and follow
@ZymeworksInc
on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]
